Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096276 · ClinicalTrials.gov registry record
Boostrix® Pregnancy Registry
A clinical trial of Pertussis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 1,517
- Enrollment target
- 1
- Study location
NCT02096276: Completed study of Pertussis, sponsored by GlaxoSmithKline.
NCT02096276 is a study of Pertussis that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,517 participants, below the 38,822-participant average among 14 other Pertussis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096276, a study of Pertussis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 1,517 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US. The Registry requires voluntary, prospective reporting of eligible pregnancies by patients and health care providers (HCPs). Data such as vaccination with Boostrix during pregnancy or within 28 days preceding conception, potential confounding factors (such as exposure to other medications) and information related to the outcome of the pregnancy will be collected prospectively
Primary Outcome
Pregnancy outcomes included live births, spontaneous abortions (pregnancy loss \<22 weeks of gestation), stillbirths (pregnancy loss ≥22 weeks of gestation) and elective terminations. Each pregnancy outcome was further classified according to the presence or absence of a birth defect.
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
North Carolina
- GSK Investigational Site - Research Triangle Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,517 participants |
| Start Date | 2014-03-31 |
| Est. Completion | 2019-08-02 |
What the finished NCT02096276 record still lists
NCT02096276 is an observational study that tracks outcomes without assigning an intervention. Its 1,517 participants enrollment target places it among the larger protocols in the corpus, below the 38,822-participant average among 14 other Pertussis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pertussis appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT02096276 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02096276 about?
NCT02096276 is a clinical study titled "Boostrix® Pregnancy Registry". The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US. The Registry requires voluntary, prospective reporting of eligible pregnancies by pati...
What is the current status of trial NCT02096276?
This trial is currently completed. The enrollment target is 1,517 participants. The study started on 2014-03-31. Estimated completion is 2019-08-02.
What conditions does trial NCT02096276 study?
This clinical trial studies the following conditions: Pertussis.
What interventions are being tested in trial NCT02096276?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT02096276?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096276 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pertussis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02096276's enrollment target sits among peer trials
1,517 4th of 14 higher than 11 of 14 other Pertussis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pertussis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
COMPLETED
-
Pentavalent DTaP-Hep B-IPV
COMPLETED · Phase 2
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI